List of Excipients in Branded Drug AMLODIPINE BESYLATE AND OLMESARTRAN MEDOXOMIL

Generic Drugs Containing AMLODIPINE BESYLATE AND OLMESARTRAN MEDOXOMIL

Company	Ingredient	NDC	Excipient
Alembic Pharmaceuticals Limited	amlodipine besylate and olmesartran medoxomil	46708-212	CELLULOSE, MICROCRYSTALLINE
Alembic Pharmaceuticals Limited	amlodipine besylate and olmesartran medoxomil	46708-212	CROSCARMELLOSE SODIUM
Alembic Pharmaceuticals Limited	amlodipine besylate and olmesartran medoxomil	46708-212	MAGNESIUM STEARATE

What are the Most Frequently-Used Excipients in AMLODIPINE BESYLATE AND OLMESARTRAN MEDOXOMIL?

# Of NDCs	Excipient
2	CELLULOSE, MICROCRYSTALLINE
2	CROSCARMELLOSE SODIUM
2	MAGNESIUM STEARATE

Amlodipine Besylate and Olmesartan Medoxomil: Excipient Strategy and Commercial Opportunities

Last updated: August 27, 2026

Amlodipine besylate/olmesartan medoxomil is a mature fixed-dose antihypertensive combination with broad generic availability. The commercial opportunity is no longer based on basic active-ingredient exclusivity. It is based on cost-efficient formulation, differentiated dosage forms, excipient substitution, supply resilience, pediatric and geriatric usability, and regional regulatory execution.

The primary formulation challenge is combining a low-dose dihydropyridine calcium-channel blocker, amlodipine, with the poorly water-soluble prodrug olmesartan medoxomil in a stable, manufacturable immediate-release tablet. A successful excipient platform must support content uniformity at amlodipine strengths of 5 mg and 10 mg, protect olmesartan medoxomil from degradation, maintain dissolution across physiological pH, and preserve low manufacturing cost.

What drug product is protected by amlodipine besylate and olmesartan medoxomil?

Amlodipine besylate/olmesartan medoxomil is an oral fixed-dose combination marketed in the United States as Azor. The active ingredients are:

• Amlodipine besylate, a long-acting calcium-channel blocker.
• Olmesartan medoxomil, an angiotensin II receptor blocker and prodrug converted to olmesartan during absorption.

The original U.S. marketed strengths are:

Strength	Amlodipine besylate	Olmesartan medoxomil
5/20 mg	5 mg	20 mg
5/40 mg	5 mg	40 mg
10/20 mg	10 mg	20 mg
10/40 mg	10 mg	40 mg

The product is indicated for hypertension and may be used when blood pressure is not adequately controlled with monotherapy or when combination therapy is clinically appropriate [1].

The product is an immediate-release, film-coated tablet. That dosage form limits the commercial value of conventional sustained-release claims but leaves room for improvements in disintegration, patient acceptability, tablet size, dose flexibility, and manufacturing efficiency.

What excipients are used in amlodipine/olmesartan tablets?

The reference product and generic products generally use standard oral solid-dose excipients. Public labeling identifies excipient families that can include microcrystalline cellulose, starch-derived binders or disintegrants, crospovidone or related superdisintegrants, colloidal silicon dioxide, magnesium stearate, talc, and colorants, depending on the strength and manufacturer [1, 2].

Because generic manufacturers can use different inactive ingredients, the precise excipient system is product-specific. FDA-approved labels and inactive-ingredient records should control any final composition assessment.

Core excipient functions

Formulation function	Candidate excipients	Commercial purpose
Dilution and compression	Microcrystalline cellulose, lactose, mannitol, dibasic calcium phosphate	Controls tablet weight, hardness, and cost
Binding	Pregelatinized starch, povidone, hydroxypropyl cellulose	Improves granule and tablet integrity
Disintegration	Crospovidone, croscarmellose sodium, sodium starch glycolate	Accelerates tablet breakup and dissolution
Flow enhancement	Colloidal silicon dioxide	Improves powder flow and die filling
Lubrication	Magnesium stearate, sodium stearyl fumarate	Reduces ejection force and tooling adhesion
Moisture management	Low-moisture cellulose, anhydrous fillers, moisture-barrier packaging	Limits hydrolytic or physical instability
Coating	Hypromellose, polyethylene glycol, titanium dioxide, iron oxides	Protects the tablet and supports product identification

The formulation should avoid unnecessary excipient complexity. A high excipient count increases supplier qualification work, analytical testing, change-control exposure, and the probability of dissolution changes after scale-up.

How does olmesartan medoxomil affect excipient selection?

Olmesartan medoxomil is the formulation-limiting active ingredient. It has low aqueous solubility and can require particle-size control, wetting improvement, or a carefully selected disintegration system to achieve consistent dissolution. Amlodipine is present at a much lower dose and creates a content-uniformity challenge rather than a loading challenge.

Three technical issues dominate development.

Low-dose amlodipine distribution

Amlodipine represents approximately 11% to 22% of the active mass in the four principal strengths. Direct blending can create segregation risk if particle size, density, or electrostatic behavior differs from the olmesartan medoxomil fraction.

A practical strategy is ordered dilution or preblending:

1. Preblend amlodipine besylate with a portion of microcrystalline cellulose or another compatible filler.
2. Add the premix incrementally to the olmesartan-containing blend.
3. Add the external disintegrant and glidant after the low-dose premix is distributed.
4. Add lubricant last, using a controlled blending time.

For larger-scale production, roller compaction can reduce moisture exposure and improve blend handling. Wet granulation may improve content uniformity but adds water, heat, drying time, and scale-up variables.

Olmesartan medoxomil dissolution

Dissolution can be improved through:

• Smaller and controlled API particle size.
• Wetting agents at low concentration.
• Hydrophilic polymer or surfactant-assisted dispersion.
• Superdisintegrant selection and optimized intragranular/extragranular distribution.
• Amorphous or partially amorphous API technologies, where stability is demonstrated.
• Spray-dried or co-processed intermediate powders.

A surfactant or polymer approach can create regulatory and stability burdens. The lowest-risk generic path is usually particle engineering combined with a conventional disintegrant and robust compression process.

Moisture and chemical stability

Olmesartan medoxomil is vulnerable to hydrolytic degradation under unsuitable conditions. A low-water process, controlled relative humidity, and moisture-protective packaging can reduce risk. Direct compression is attractive where powder flow and content uniformity are acceptable. Dry granulation is a stronger alternative where flow, segregation, or compressibility prevents reliable direct compression.

What formulation patents protect amlodipine and olmesartan combinations?

The original combination product was protected by composition and formulation patents associated with Daiichi Sankyo and related commercial entities. U.S. Patent No. 6,441,050 covered pharmaceutical compositions containing olmesartan medoxomil and amlodipine and was listed in connection with Azor during the product’s protected period [3, 4].

The main patent barriers are now historical rather than commercial:

IP category	Relevance to the combination	Current commercial effect
Olmesartan medoxomil compound patents	Protected the ARB active ingredient	Expired
Amlodipine compound patents	Protected the calcium-channel blocker	Expired
Combination composition patents	Covered combined administration or dosage forms	Original term expired
Formulation patents	May cover dissolution, particle size, or excipient systems	Must be screened claim by claim
Method-of-use patents	May cover hypertension treatment populations or dosing	Limited value where claims have expired or are not listed
Manufacturing patents	May cover API production or solid-state forms	Can remain relevant to API sourcing

A new excipient composition can create patentable subject matter only if it produces a non-obvious technical effect, such as materially improved stability, dissolution, manufacturability, or bioavailability. A conventional substitution of lactose for microcrystalline cellulose generally has weak patent value unless supported by unexpected performance.

When does amlodipine/olmesartan lose exclusivity?

The product has already lost core U.S. exclusivity. The original combination patent term expired in or around 2020, and FDA-approved generic products are commercially available [3, 4].

The principal market-entry milestones were:

Event	Approximate timing
U.S. FDA approval of Azor	2007
Original combination patent protection	Expired around 2020
Generic approvals	Began after the relevant patent and exclusivity barriers ended
Current status	Mature multi-source generic market

Amlodipine and olmesartan are also independently generic. A new entrant therefore faces price competition from both single-ingredient products and fixed-dose combinations.

What is the Orange Book status of Azor?

Azor has been listed in the FDA Orange Book as a reference product for amlodipine besylate and olmesartan medoxomil tablets. The applicable listed patent protection for the original combination has expired, and generic approvals have been granted through the abbreviated new drug application pathway [3, 4].

Paragraph IV litigation is no longer the central market issue for the original product. A new generic applicant would ordinarily evaluate:

• Any remaining Orange Book-listed patents.
• Unexpired formulation or method-of-use claims.
• Patent claims covering the API source or solid-state form.
• Litigation risk arising from a newly patented delivery system.
• State or federal substitution rules affecting pharmacy uptake.

For a conventional immediate-release tablet, regulatory and commercial execution matter more than Paragraph IV strategy.

What excipient strategy is most commercially attractive?

The best commercial platform is a low-cost, low-moisture, direct-compression or dry-granulation system with broad raw-material sourcing.

Strategy 1: Conventional direct compression

A conventional blend based on microcrystalline cellulose, a superdisintegrant, colloidal silicon dioxide, and magnesium stearate offers the lowest manufacturing complexity.

Advantages include:

• Short process cycle.
• Low capital requirements.
• No granulation solvent or drying step.
• Simple scale-up.
• Broad availability of excipient grades.

The main risks are segregation, variable flow, lubricant sensitivity, and insufficient dissolution of olmesartan medoxomil.

Strategy 2: Dry granulation

Roller compaction can improve flow, density, and blend uniformity while avoiding water. It is commercially attractive for high-volume generic production where tablet weight, dust control, and feeding consistency affect line performance.

The formulation must control ribbon density and milling conditions. Excessive compaction can slow disintegration and dissolution.

Strategy 3: Lactose-free formulation

A lactose-free product can target patients with lactose intolerance and markets where lactose labeling creates commercial friction. Mannitol, microcrystalline cellulose, dibasic calcium phosphate, or starch can replace lactose.

Mannitol improves mouthfeel but can raise cost and alter compactibility. Dibasic calcium phosphate offers good flow and compression but may affect dissolution and can be unsuitable for certain API compatibility profiles.

The opportunity is strongest in hospital, tender, and specialty-pharmacy channels where clean-label or lactose-free claims influence purchasing.

Strategy 4: Large-scale pediatric or geriatric product

A dispersible tablet, oral granule, or extemporaneous suspension kit could create differentiation. The opportunity is technically more demanding because olmesartan medoxomil taste, dose uniformity, suspension stability, and device accuracy must be controlled.

FDA labeling for Azor is directed primarily to standard oral tablet use. A pediatric formulation would require a separate regulatory strategy and potentially new clinical or bridging evidence [1].

What commercial opportunities exist for excipient suppliers?

Excipient suppliers can compete in four areas.

Co-processed excipients

A co-processed filler-disintegrant system can reduce development time by improving flow, compactibility, and tablet breakup. The value proposition is strongest when the formulation has a narrow compression window or needs high-speed tableting.

Low-moisture excipients

Anhydrous or low-moisture grades can support dry processing and reduce degradation risk. Suppliers can differentiate through water activity control, lot-to-lot consistency, and global regulatory documentation.

Functionalized lubricants

Sodium stearyl fumarate or optimized magnesium stearate grades can reduce over-lubrication risk. This matters where dissolution is sensitive to hydrophobic lubricant coating.

Taste-masking and liquid systems

Taste-masking polymers, ion-exchange resins, and suspension stabilizers are relevant to pediatric or dysphagia-oriented products. These systems create higher-value opportunities than standard tablet fillers but face greater regulatory and intellectual-property requirements.

How strong is the patent estate for a new excipient-based formulation?

The patent estate for a conventional tablet is weak unless the formulation produces a measurable and unexpected result. Stronger claim opportunities include:

• A defined particle-size distribution for olmesartan medoxomil.
• A specific excipient ratio that improves dissolution after storage.
• A dry-granulated intermediate with controlled density.
• A moisture-protective formulation with defined impurity limits.
• A dispersible dosage form with rapid uniform dispersion.
• A stable liquid or multiparticulate formulation.
• A novel packaging and formulation combination that maintains stability in high humidity.

Claims should be supported by comparative data against a conventional formulation. Dissolution at multiple pH values, assay uniformity, degradation products, tablet tensile strength, friability, and accelerated stability are central evidence categories.

Which companies are challenging or competing with Azor?

Competition comes from three groups:

1. Generic manufacturers of amlodipine/olmesartan tablets.
2. Suppliers of the individual generic components.
3. Alternative fixed-dose antihypertensive combinations.

Generic competition has included major and mid-sized manufacturers such as Teva, Lupin, Torrent, Zydus, and other ANDA holders, subject to product-specific approval and marketing status. The market is fragmented, and actual commercial availability varies by strength, channel, and procurement contract.

Competitive substitutes include:

Product class	Examples	Competitive effect
ARB/calcium-channel blocker combinations	Olmesartan/amlodipine, valsartan/amlodipine, telmisartan/amlodipine	Direct therapeutic substitution
ARB/thiazide combinations	Olmesartan/hydrochlorothiazide	Competes where diuretic therapy is preferred
Single-agent therapy	Generic amlodipine or olmesartan	Lower-cost titration alternative
Triple therapy	Olmesartan/amlodipine/hydrochlorothiazide	Competes in uncontrolled hypertension

The commercial advantage of a fixed-dose product is adherence and prescription simplicity. Its disadvantage is reduced dose flexibility compared with separate tablets.

What generic launch risks exist?

The principal launch risks are operational:

• API particle-size variation affecting dissolution.
• Amlodipine segregation during blending.
• Failure to match reference-product dissolution profiles.
• Lubrication-induced dissolution slowdown.
• Moisture-related impurity growth.
• Colorant or coating differences that complicate bioequivalence batches.
• Tablet weight increases that reduce patient acceptability.
• Supply interruption for a specialty excipient grade.
• Failure to support all four strengths with one scalable platform.

FDA ANDA development requires pharmaceutical equivalence and bioequivalence to the reference product. The applicant must also demonstrate acceptable stability, impurity control, manufacturing reproducibility, and inactive-ingredient compliance [5].

How does this product compare with newer antihypertensive combinations?

Amlodipine/olmesartan has a mature safety and manufacturing profile but limited exclusivity. Newer commercial products may offer stronger differentiation through triple therapy, longer-acting delivery, combination with newer agents, or patient-specific dose flexibility.

Attribute	Amlodipine/olmesartan	Newer combination product
Core IP	Mostly expired	May have active formulation or combination claims
Manufacturing	Conventional tablet platform	May require complex delivery technology
Price pressure	High	Depends on exclusivity
Adherence benefit	Fixed-dose combination	Potentially greater with triple or once-daily products
Excipient differentiation	Moderate	Often higher
Regulatory risk	Relatively low for standard generic	Higher if new dosage form or indication is pursued

What geographic opportunities exist?

The strongest near-term opportunity is in regulated markets with established generic substitution, including the United States, Europe, Japan, Canada, Australia, and selected Latin American markets.

Emerging-market opportunities depend on:

• Local registration requirements.
• Government tender pricing.
• API sourcing and local manufacturing rules.
• Stability requirements for hot and humid climates.
• Availability of blister packaging and moisture-barrier bottles.
• Physician acceptance of fixed-dose combinations.

High-humidity markets favor moisture-controlled formulations and alu-alu blister packaging. Tender markets favor the lowest fully loaded cost, simple supply chains, and a small number of excipient grades.

Key Takeaways

• Amlodipine besylate/olmesartan medoxomil is a mature generic fixed-dose combination.
• Core compound and combination patent barriers have expired or lost practical commercial significance.
• Olmesartan medoxomil is the main formulation challenge because of solubility and dissolution constraints.
• Amlodipine creates a low-dose content-uniformity and segregation challenge.
• Direct compression is the lowest-cost platform; dry granulation is the strongest alternative when flow or blend uniformity is inadequate.
• Lactose-free, low-moisture, dispersible, pediatric, and geriatric formulations offer the clearest differentiation paths.
• A conventional excipient substitution has limited patent strength without unexpected performance data.
• Commercial success depends on dissolution robustness, API control, excipient supply security, packaging, and tender economics.
• Biosimilar risk is not relevant because both active ingredients are small-molecule drugs, not biologics.
• The most defensible new IP would cover a defined formulation, process, stability profile, or patient-friendly dosage form.

FAQs

Is olmesartan medoxomil a biologic that can face biosimilar competition?

No. Olmesartan medoxomil and amlodipine are small-molecule drugs. Competition proceeds through generic drug pathways, primarily ANDAs in the United States, rather than biosimilar applications.

Can a new excipient create market exclusivity for this combination?

An excipient alone rarely creates meaningful exclusivity. A patent may be commercially useful when a specific excipient system produces unexpected improvements in dissolution, stability, manufacturability, or patient administration.

Is a liquid amlodipine/olmesartan product commercially feasible?

Yes, but it requires control of olmesartan medoxomil dispersion, taste, sedimentation, chemical stability, dose uniformity, preservative strategy, and packaging. It would be a differentiated product rather than a simple generic tablet substitute.

Which packaging is most suitable for high-humidity markets?

Aluminum-aluminum blister packaging generally provides stronger moisture protection than standard PVC blister systems. High-density polyethylene bottles with desiccant can also be suitable when container-closure performance is demonstrated.

Does combining amlodipine and olmesartan reduce the number of tablets patients take?

Yes. A fixed-dose combination can replace two separate tablets, although it reduces independent titration flexibility. The adherence benefit is commercially relevant in chronic hypertension management.

References

1. U.S. Food and Drug Administration. (2023). Azor (amlodipine besylate and olmesartan medoxomil) prescribing information.
2. U.S. National Library of Medicine. (2024). DailyMed: Amlodipine besylate and olmesartan medoxomil tablet labeling.
3. U.S. Patent and Trademark Office. (2002). U.S. Patent No. 6,441,050: Pharmaceutical composition containing olmesartan medoxomil and amlodipine.
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
5. U.S. Food and Drug Administration. (2023). Abbreviated new drug application submissions: Product-specific guidance for amlodipine besylate and olmesartan medoxomil tablets.